Printer Friendly

DEPRENYL USA, INC. RECEIVES NEW PATENTS

 DENVILLE, N.J., April 12 /PRNewswire/ -- Deprenyl USA, Inc. (NASDAQ: DUSA) today announced that two new patent applications related to its lead product, ALA Photodynamic Therapy (PDT), have been allowed by the United States Patent and Trademark office.
 One involves the use of ALA PDT for diseases of the uterus. This covers its potential use as a non-surgical alternative to hysterectomy for women with excessive uterine bleeding.
 The second covers the use of ALA PDT as a diagnostic agent for cancer.
 Patent allowance was also received on a series of new experimental compounds for PDT of internal cancers, which the company has under option from Queen's University at Kingston, Ontario.
 Deprenyl USA is a development stage company established to bring prescription pharmaceutical products to worldwide markets, initially in the United States and Canada, primarily in the field of photodynamic therapy.
 The company recently announced that it will change its name to DUSA Pharmaceuticals, Inc., subject to shareholder approval at the annual meeting to be held May 26, 1993. Also, as of April 1, the company moved its New Jersey offices to 66 Ford Road, Suite 121, Denville, N.J. 201-625-4460.
 Common stock and warrants are traded on NASDAQ under the symbols DUSA and DUSAW. They also trade on the Toronto Stock Exchange under the symbols DPU and DPU.WT.
 -0- 4/12/93
 /CONTACT: D. Geoffrey Shulman, M.D., FRCPC, president and CEO, 416-537-1070 or (fax) 416-537-0258, or Joseph P. Castelli, vice president, 201-625-4460 or (fax) 201-625-8040, both of Deprenyl USA; or Jim Tolan, senior vice president, or Nicholas Biro, partner of O'Connor Biro & Associates, 708-498-2284 or (fax) 708-498-3144, for Deprenyl/
 (DUSA)


CO: Deprenyl USA, Inc. ST: New Jersey IN: MTC SU:

TS -- NY024 -- 4693 04/12/93 10:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 12, 1993
Words:291
Previous Article:ERC EXPERIENCES TECHNICAL DIFFICULTY WITH FUEL CELL TEST AFTER 250 HOURS OF OPERATION; SECOND TEST PLANNED FOR AUGUST
Next Article:SURETY CAPITAL CORPORATION QUARTER OPERATING RESULTS
Topics:


Related Articles
DEPRENYL ACQUIRES CONTROL OF QUEBEC-BASED LIPOPHARM INC.
DEPRENYL USA REPORTS RESULTS FOR SECOND QUARTER AND SIX MONTHS ENDING JUNE 30, 1992
DEPRENYL USA ANNOUNCES NO CHANGE AT COMPANY TO ACCOUNT FOR SHARE PRICE PRESSURE
DEPRENYL USA, INC. SIGNS AGREEMENT ON ADDITIONAL PHOTODYNAMIC CANCER FIGHTING COMPOUNDS
DEPRENYL USA COMMENCES INITIAL CONTROLLED HUMAN CLINICAL TRIALS
DEPRENYL USA COMMENCES INITIAL CONTROLLED HUMAN CLINICAL TRIALS
DEPRENYL USA REPORTS YEAR END 1992 RESULTS; CONFIRMS ALA PHOTODYNAMIC DEVELOPMENT ON SCHEDULE; PROPOSES NAME CHANGE TO DUSA PHARMACEUTICALS
DEPRENYL USA, INC. ENGAGES CANADIAN INVESTMENT DEALER
DEPRENYL USA REPORTS FIRST QUARTER RESULTS ON PLAN INITIAL CLINICAL TRIALS PROCEEDING ON SCHEDULE
INTRODUCTION OF GENERIC PARKINSON DRUG TO HELP PATIENTS AND PROVINCIAL GOVERNMENTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters